Related Experiment Videos
Gastrointestinal patch systems for oral drug delivery
1Department of Physiology, University of California, San Francisco, CA 94143, USA.
Drug Discovery Today
|July 5, 2005
Summary
Novel gastrointestinal patches offer improved oral delivery for large molecules, overcoming injection limitations. These advanced systems enhance drug bioavailability and enable targeted, controlled release for better therapeutic outcomes.
Area of Science:
- Pharmaceutical Sciences
- Biomaterials Engineering
- Drug Delivery Systems
Background:
- Conventional drug delivery faces challenges with large molecules, often requiring injections.
- Existing methods struggle with bioavailability and targeted delivery of complex therapeutics.
- Large molecules like epoetin-alpha and granulocyte-colony-stimulating factor have limited oral delivery options.
Purpose of the Study:
- To explore the potential of multifunctional gastrointestinal patch systems for enhanced oral drug delivery.
- To investigate how integrated functions in patches can overcome limitations of conventional delivery.
- To assess the feasibility of delivering large molecules orally using advanced patch technology.
Main Methods:
- Development of gastrointestinal patch systems with integrated bioadhesion, drug protection, and unidirectional release.
- Incorporation of self-regulated release mechanisms.
- Integration of cell-specific targeting capabilities.
Main Results:
- Gastrointestinal patch systems demonstrate potential for improved oral bioavailability of large molecules.
- The combination of bioadhesion, protection, and unidirectional release enhances therapeutic efficacy.
- Self-regulated release and cell-specific targeting add 'smart' functionalities to the platform.
Conclusions:
- Multifunctional gastrointestinal patches represent an innovative platform for oral delivery of large molecules.
- This technology could provide an alternative to injections for biologics like epoetin-alpha and G-CSF.
- Further development promises advanced, targeted, and controlled oral therapeutics.